ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met

Xu, Xin; Jiang, Wenjing; Han, Peng; Zhang, Jingyan; Tong, Liquan*; Sun, Xueying*哈尔滨医科大学; 1; 5
Journal of Hepatocellular Carcinoma2022DOI: 10.2147/JHC.S349369
13被引7阅读
引用收藏
分享

摘要

Objective: Lenvatinib is a first-line multikinase inhibitor for advanced hepatocellular carcinoma (HCC), but resistance to the drug remains a major hurdle for its long-term anti-cancer activity. This resistance is thought to be due to overexpression of c-Met. This study aims to identify potential upstream microRNAs (miRNAs) that regulate c-Met, investigate the underlying mechanisms, and seek potential strategies that may reverse such resistance. Methods: Lenvatinib-resistant HCC (LR-HCC) cells were established from human HCC Huh7 and SMMC-7721 cells. Assays of cell proliferation, cell cycle distribution, apoptosis, RT-qPCR, Western blot analysis and immunohistochemistry were employed. Potential miRNAs were screened by miRNA-target prediction tools and their regulatory effects were evaluated by luciferase reporter assays. Xenograft tumor models were used to evaluate the therapeutic effects. Results: LR-HCC cells were refractory to lenvatinib-induced growth inhibition and apoptosis in vitro and in vivo. Sustained exposure of cells to lenvatinib resulted in increased expression and phosphorylation of c-Met, and c-Met inhibition enhanced the effects of lenvatinib in suppressing LR-HCC cells. Among eleven miRNA candidates, miR-128-3p displayed the most vigorous activity to negatively regulate c-Met and was downregulated in LR-HCC cells. MiR-128-3p mimics inhibited proliferation and induced apoptosis of LR-HCC cells, and enhanced the effects of lenvatinib in cell culture and animal models. MiR-128-3p and c-Met participate in the mechanisms underlying lenvatinib resistance through regulating Akt that mediates the apoptotic pathway and ERK (extracellular-signal-regulated kinase) modulating cell cycle progression. Conclusion: The present results indicate that the miR-128-3p/c-Met axis may be potential therapeutic targets for circumventing lenvatinib resistance in HCC and warrant further investigation.

学科与关键词

关键词
hepatocellular carcinomalenvatinibdrug resistancec-MetmicroRNA-128-3p
相关
加载中…
  • Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
    Fu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
  • Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagy
    Zhang, Yuxin; Zhang, Yujie; Tao, Haisu; Zhu, Jinghan; Lu, Yuanxiang; Cheng, Fangling; Xiong, Yixiao; Liu, Junjie; Cai, Guangzhen; Zhang, Zhanguo*; Liang, Huifang*; Chen, Yifa*; Zhang, Wanguang*Cancer Letters, 2023, 576: 216405.被引 1
  • Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
    Huang, Shanzhou; Ma, Zuyi; Zhou, Qi; Wang, Aimei; Gong, Yuanfeng; Li, Zhenchong; Wang, Shujie; Yan, Qian; Wang, Dongping*; Hou, Baohua*; Zhang, Chuanzhao*International Journal of Biological Sciences, 2022, 18(11): 4357-4371.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Hepatocellular Carcinoma
发表日期
2022
卷期
第 9 卷
页码
113-126
DOI
10.2147/JHC.S349369
期刊等级
3区
成果收录
SCIE
资助标注
National Key Research and Development Program of China [2017YFC1308602]; National Natural Scientific Foundation of China [81803010]; Heilongjiang Provincial Natural Scientific Foundation [LH2019H006]; Heilongjiang Provincial Federation of Trade Unions [2020-12-16]

作者

  • X

    Xu, Xin (第一作者)

    1 · harbin med univ · daqing oil field gen hosp

  • J

    Jiang, Wenjing

    1 · harbin med univ

查看全部 6 位作者收起作者
  • H

    Han, Peng

    1 · harbin med univ

  • Z

    Zhang, Jingyan

    5 · harbin med univ

  • T

    Tong, Liquan (通讯)

    5 · harbin med univ

  • S

    Sun, Xueying (通讯)

    1 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417